Molecular subtyping of gastric cancer combining genetic and epigenetic anomalies provides distinct clinicopathological features and prognostic impacts

Tomomitsu Tahara, Sayumi Tahara, Noriyuki Horiguchi, Masaaki Okubo, Tsuyoshi Terada, Hyuga Yamada, Dai Yoshida, Takafumi Omori, Hayato Osaki, Kohei Maeda, Toshiaki Kamano, Kohei Funasaka, Mitsuo Nagasaka, Yoshihito Nakagawa, Tomoyuki Shibata, Naoki Omiya

Research output: Contribution to journalArticle

Abstract

Both genetic and epigenetic abnormalities play important roles in gastric cancer (GC) development. We investigated whether the molecular subtypes of gastric cancer by combining genetic and epigenetic anomalies define its clinicopathological features and prognosis. The CpG island methylator phenotype (CIMP), MLH1 methylation, TP53, and KRAS mutation statuses were characterized in 214 GCs in relation to their clinicopathological features and prognosis. The molecular subtypes based on CIMP and TP53 hot spot mutation status (R175, G245, R248, R273, and R282) best predicted prognosis of GC. These subtypes contained 120 CIMP-positive (CIMP+) TP53 hot spot mutation-negative (TP53 hot spot–) cases, 81 CIMP-negative (CIMP–) TP53 hot spot– cases, 8 CIMP+TP53 hot spot mutation-positive (TP53 hot spot+) cases, and 5 CIMP– TP53 hot spot+ cases. The CIMP–TP53 hot spot+ group presented the worst overall survival (OS) and progression-free survival (PFS), followed by the CIMP+TP53 hot spot+, CIMP–TP53 hot spot– and CIMP+TP53 hot spot– groups (both P < 0.0001). These subtypes also correlated well with several aggressive clinicopathological features in that order. The molecular subtypes were independent factors for predicting overall survival (hazard ratio = 1.66, 95% CI = 1.07–2.57, P = 0.006). The molecular subtypes combining the CIMP and TP53 hot spot mutation status provide distinct clinicopathological features and prognostic impacts in GC.

Original languageEnglish
Pages (from-to)347-354
Number of pages8
JournalHuman Mutation
Volume40
Issue number3
DOIs
Publication statusPublished - 01-03-2019

Fingerprint

CpG Islands
Epigenomics
Stomach Neoplasms
Phenotype
Mutation
Methylation
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Genetics
  • Genetics(clinical)

Cite this

Tahara, Tomomitsu ; Tahara, Sayumi ; Horiguchi, Noriyuki ; Okubo, Masaaki ; Terada, Tsuyoshi ; Yamada, Hyuga ; Yoshida, Dai ; Omori, Takafumi ; Osaki, Hayato ; Maeda, Kohei ; Kamano, Toshiaki ; Funasaka, Kohei ; Nagasaka, Mitsuo ; Nakagawa, Yoshihito ; Shibata, Tomoyuki ; Omiya, Naoki. / Molecular subtyping of gastric cancer combining genetic and epigenetic anomalies provides distinct clinicopathological features and prognostic impacts. In: Human Mutation. 2019 ; Vol. 40, No. 3. pp. 347-354.
@article{97a97650d106482fa26a0f2f843e62c3,
title = "Molecular subtyping of gastric cancer combining genetic and epigenetic anomalies provides distinct clinicopathological features and prognostic impacts",
abstract = "Both genetic and epigenetic abnormalities play important roles in gastric cancer (GC) development. We investigated whether the molecular subtypes of gastric cancer by combining genetic and epigenetic anomalies define its clinicopathological features and prognosis. The CpG island methylator phenotype (CIMP), MLH1 methylation, TP53, and KRAS mutation statuses were characterized in 214 GCs in relation to their clinicopathological features and prognosis. The molecular subtypes based on CIMP and TP53 hot spot mutation status (R175, G245, R248, R273, and R282) best predicted prognosis of GC. These subtypes contained 120 CIMP-positive (CIMP+) TP53 hot spot mutation-negative (TP53 hot spot–) cases, 81 CIMP-negative (CIMP–) TP53 hot spot– cases, 8 CIMP+TP53 hot spot mutation-positive (TP53 hot spot+) cases, and 5 CIMP– TP53 hot spot+ cases. The CIMP–TP53 hot spot+ group presented the worst overall survival (OS) and progression-free survival (PFS), followed by the CIMP+TP53 hot spot+, CIMP–TP53 hot spot– and CIMP+TP53 hot spot– groups (both P < 0.0001). These subtypes also correlated well with several aggressive clinicopathological features in that order. The molecular subtypes were independent factors for predicting overall survival (hazard ratio = 1.66, 95{\%} CI = 1.07–2.57, P = 0.006). The molecular subtypes combining the CIMP and TP53 hot spot mutation status provide distinct clinicopathological features and prognostic impacts in GC.",
author = "Tomomitsu Tahara and Sayumi Tahara and Noriyuki Horiguchi and Masaaki Okubo and Tsuyoshi Terada and Hyuga Yamada and Dai Yoshida and Takafumi Omori and Hayato Osaki and Kohei Maeda and Toshiaki Kamano and Kohei Funasaka and Mitsuo Nagasaka and Yoshihito Nakagawa and Tomoyuki Shibata and Naoki Omiya",
year = "2019",
month = "3",
day = "1",
doi = "10.1002/humu.23700",
language = "English",
volume = "40",
pages = "347--354",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "3",

}

Tahara, T, Tahara, S, Horiguchi, N, Okubo, M, Terada, T, Yamada, H, Yoshida, D, Omori, T, Osaki, H, Maeda, K, Kamano, T, Funasaka, K, Nagasaka, M, Nakagawa, Y, Shibata, T & Omiya, N 2019, 'Molecular subtyping of gastric cancer combining genetic and epigenetic anomalies provides distinct clinicopathological features and prognostic impacts', Human Mutation, vol. 40, no. 3, pp. 347-354. https://doi.org/10.1002/humu.23700

Molecular subtyping of gastric cancer combining genetic and epigenetic anomalies provides distinct clinicopathological features and prognostic impacts. / Tahara, Tomomitsu; Tahara, Sayumi; Horiguchi, Noriyuki; Okubo, Masaaki; Terada, Tsuyoshi; Yamada, Hyuga; Yoshida, Dai; Omori, Takafumi; Osaki, Hayato; Maeda, Kohei; Kamano, Toshiaki; Funasaka, Kohei; Nagasaka, Mitsuo; Nakagawa, Yoshihito; Shibata, Tomoyuki; Omiya, Naoki.

In: Human Mutation, Vol. 40, No. 3, 01.03.2019, p. 347-354.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Molecular subtyping of gastric cancer combining genetic and epigenetic anomalies provides distinct clinicopathological features and prognostic impacts

AU - Tahara, Tomomitsu

AU - Tahara, Sayumi

AU - Horiguchi, Noriyuki

AU - Okubo, Masaaki

AU - Terada, Tsuyoshi

AU - Yamada, Hyuga

AU - Yoshida, Dai

AU - Omori, Takafumi

AU - Osaki, Hayato

AU - Maeda, Kohei

AU - Kamano, Toshiaki

AU - Funasaka, Kohei

AU - Nagasaka, Mitsuo

AU - Nakagawa, Yoshihito

AU - Shibata, Tomoyuki

AU - Omiya, Naoki

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Both genetic and epigenetic abnormalities play important roles in gastric cancer (GC) development. We investigated whether the molecular subtypes of gastric cancer by combining genetic and epigenetic anomalies define its clinicopathological features and prognosis. The CpG island methylator phenotype (CIMP), MLH1 methylation, TP53, and KRAS mutation statuses were characterized in 214 GCs in relation to their clinicopathological features and prognosis. The molecular subtypes based on CIMP and TP53 hot spot mutation status (R175, G245, R248, R273, and R282) best predicted prognosis of GC. These subtypes contained 120 CIMP-positive (CIMP+) TP53 hot spot mutation-negative (TP53 hot spot–) cases, 81 CIMP-negative (CIMP–) TP53 hot spot– cases, 8 CIMP+TP53 hot spot mutation-positive (TP53 hot spot+) cases, and 5 CIMP– TP53 hot spot+ cases. The CIMP–TP53 hot spot+ group presented the worst overall survival (OS) and progression-free survival (PFS), followed by the CIMP+TP53 hot spot+, CIMP–TP53 hot spot– and CIMP+TP53 hot spot– groups (both P < 0.0001). These subtypes also correlated well with several aggressive clinicopathological features in that order. The molecular subtypes were independent factors for predicting overall survival (hazard ratio = 1.66, 95% CI = 1.07–2.57, P = 0.006). The molecular subtypes combining the CIMP and TP53 hot spot mutation status provide distinct clinicopathological features and prognostic impacts in GC.

AB - Both genetic and epigenetic abnormalities play important roles in gastric cancer (GC) development. We investigated whether the molecular subtypes of gastric cancer by combining genetic and epigenetic anomalies define its clinicopathological features and prognosis. The CpG island methylator phenotype (CIMP), MLH1 methylation, TP53, and KRAS mutation statuses were characterized in 214 GCs in relation to their clinicopathological features and prognosis. The molecular subtypes based on CIMP and TP53 hot spot mutation status (R175, G245, R248, R273, and R282) best predicted prognosis of GC. These subtypes contained 120 CIMP-positive (CIMP+) TP53 hot spot mutation-negative (TP53 hot spot–) cases, 81 CIMP-negative (CIMP–) TP53 hot spot– cases, 8 CIMP+TP53 hot spot mutation-positive (TP53 hot spot+) cases, and 5 CIMP– TP53 hot spot+ cases. The CIMP–TP53 hot spot+ group presented the worst overall survival (OS) and progression-free survival (PFS), followed by the CIMP+TP53 hot spot+, CIMP–TP53 hot spot– and CIMP+TP53 hot spot– groups (both P < 0.0001). These subtypes also correlated well with several aggressive clinicopathological features in that order. The molecular subtypes were independent factors for predicting overall survival (hazard ratio = 1.66, 95% CI = 1.07–2.57, P = 0.006). The molecular subtypes combining the CIMP and TP53 hot spot mutation status provide distinct clinicopathological features and prognostic impacts in GC.

UR - http://www.scopus.com/inward/record.url?scp=85060132756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060132756&partnerID=8YFLogxK

U2 - 10.1002/humu.23700

DO - 10.1002/humu.23700

M3 - Article

C2 - 30575210

AN - SCOPUS:85060132756

VL - 40

SP - 347

EP - 354

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 3

ER -